Drug Type Drug conjugates |
Synonyms BL 0020, BL0020 |
Target |
Action inhibitors |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC22H20N2O5 |
InChIKeyFJHBVJOVLFPMQE-QFIPXVFZSA-N |
CAS Registry86639-52-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 17 Oct 2023 | |
Pancreatic Cancer | Phase 1 | Australia | 17 Oct 2023 | |
Small Cell Lung Cancer | Phase 1 | Australia | 17 Oct 2023 | |
Triple Negative Breast Cancer | Phase 1 | Australia | 17 Oct 2023 | |
Solid tumor | IND Approval | United States | 30 Nov 2023 |